NRN1 as a therapeutic target for Alzheimer's disease

Authors:

Abstract
INTRODUCTION: Neuritin‐1 (NRN1) was identified as a synaptic protein associated with cognitive resilience to Alzheimer's disease (AD). METHODS: Target risk score and cell type expression profiles were generated for NRN1 using methods developed by the Emory‐Sage‐SGC‐JAX Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT‐AD) Center and Seattle Alzheimer's Disease Brain Cell Atlas (SEA‐AD). Antibody characterization was conducted using Western blots and densitometry to assess the relative protein abundances of NRN1 in rodents, humans, and cell models. RESULTS: NRN1 has a TREAT‐AD target risk score of 3.29 out of 5. Based on single‐nucleus RNA sequencing from SEA‐AD, NRN1 expression in excitatory neurons tends to decrease with increasing donor pseudo‐progression. Abcam ab64186 polyclonal NRN1 antibody detects NRN1 protein in vitro and in vivo at molecular weights that suggest NRN1 forms a homodimer. NRN1 protein abundance is comparable among controls and primary tauopathy cases, as well as Tau P301S mice and non‐transgenic littermates at 3 and 9 months. DISCUSSION: These findings advance the investigation of NRN1 as a therapeutic candidate for AD.
Funding Information
  • National Institutes of Health (T32 NS061788 (D.A.P.))
  • National Institutes of Health (F31 AG084195 (D.A.P.))
  • National Institutes of Health (R01 AG061800 (J.H.H. and N.T.S.))
  • National Institutes of Health (R21AG085379 (J.H.H.))
  • National Institutes of Health (P30AG086401)
  • National Institutes of Health (R01NS128031)
  • National Institutes of Health (U54AG065187)
  • National Institute of Neurological Disorders and Stroke (NS061788)
  • National Institute on Aging (AG084195)

This publication has 73 references indexed in Scilit: